<DOC>
	<DOCNO>NCT01977508</DOCNO>
	<brief_summary>Multicentre , prospective , observational post-market registry . To monitor collect data post-market clinical safety performance Vascutek Rapidax II Vascular Access Graft .</brief_summary>
	<brief_title>The Vascutek Rapidax™ II Post Market Surveillance Registry</brief_title>
	<detailed_description>At least 10 patient implant Rapidax II Vascular Access Graft haemodialysis application patient End Stage Renal Disease ( ESRD ) , undergo schedule begin haemodialysis require implant prosthetic graft . Primary End Points : Safety Performance - Secondary patency 6 month post implant ( Performance ) . ( access survival abandonment ) . The interval time implant abandonment time measurement patency , include intervention re-establish functionality thrombose access - Secondary patency 12 month post implant ( Performance . ( access survival abandonment ) . The interval time implant abandonment time measurement patency , include intervention re-establish functionality thrombose access - Freedom device relate Serious Adverse Events 6 12 month ( Safety ) Secondary End Points : Safety performance - Primary patency 6 month post implant ( Performance . ( intervention free access survival ) . The interval time implant intervention design maintain re-establish patency access thrombosis - Primary patency 12 month post implant ( Performance ) . ( intervention free access survival ) . The interval time implant intervention design maintain re-establish patency access thrombosis - Assisted primary patency 6 month ( Performance . ( thrombosis free access survival ) . The interval time implant intervention maintain patency prior occurrence thrombosis - Freedom device relate Serious Adverse Events 6 12 month</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject ≥ 18 ≤ 90 year old 2 . Subject life expectancy least 12 month 3 . Subject schedule undergo placement new straight loop arm arteriovenous haemodialysis access graft 4 . The subject willing able comply protocol associate follow requirement 5 . Subjects must agree data enter registry per local hospital consent procedure 1 . Known allergy sensitivity ePTFE 2 . Subject unwilling unable comply protocol 3 . Life expectancy less 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vascular access graft</keyword>
	<keyword>Haemodialysis</keyword>
</DOC>